Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma
Xiaoju Huang,Mengmeng Wang,Dan Zhang,Chen Zhang,Pian Liu
DOI: https://doi.org/10.2147/jhc.s447578
2024-01-17
Journal of Hepatocellular Carcinoma
Abstract:Xiaoju Huang, 1– 3 Mengmeng Wang, 1– 3 Dan Zhang, 1– 3 Chen Zhang, 4 Pian Liu 1– 3 1 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 3 Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, People's Republic of China; 4 Liver Transplant Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China Correspondence: Chen Zhang; Pian Liu, Email ; Hepatocellular carcinoma is the prevailing malignant neoplasm affecting the liver, often diagnosed at an advanced stage and associated with an unfavorable overall prognosis. Sorafenib and Lenvatinib have emerged as first-line therapeutic drugs for advanced hepatocellular carcinoma, improving the prognosis for these patients. Nevertheless, the issue of tyrosine kinase inhibitor (TKI) resistance poses a substantial obstacle in the management of advanced hepatocellular carcinoma. The pathogenesis and advancement of hepatocellular carcinoma exhibit a close association with metabolic reprogramming, yet the attention given to lipid metabolism dysregulation in hepatocellular carcinoma development remains relatively restricted. This review summarizes the potential significance and research progress of lipid metabolism dysfunction in Sorafenib and Lenvatinib resistance in hepatocellular carcinoma. Targeting hepatocellular carcinoma lipid metabolism holds promising potential as an effective strategy to overcome hepatocellular carcinoma drug resistance in the future. Keywords: hepatocellular carcinoma, lipid metabolism, sorafenib, lenvatinib, targeted drug resistance Liver cancer ranks as the sixth most prevalent cancer globally and stands as the third principal contributor to cancer-related mortality. 1 The most common subtype of primary liver cancer is hepatocellular carcinoma, accounting for 75–85% of liver cancer cases. 2 Owing to its subtle onset, considerable invasiveness, and absence of early manifestations, a significant proportion of patients receive diagnoses during the intermediate to advanced stages, with approximately 70% experiencing recurrent metastasis following surgical resection. 3 Notably, tyrosine kinase inhibitors (TKIs) such as Sorafenib and Lenvatinib have emerged as pivotal agents for first-line molecular targeted therapy in advanced hepatocellular carcinoma. 4,5 Additionally, Regorafenib, Cabozantinib, and Ramucirumab have been endorsed as second-line therapeutic options for hepatocellular carcinoma. 6–8 Furthermore, the clinical efficacy of immune checkpoint inhibitors (ICI), 9 anti-angiogenic agents, 10 and other targeted therapies, such as EGFR inhibitors, 11 has progressively manifested, thereby broadening the therapeutic possibilities for advanced hepatocellular carcinoma. The presence of clinical drug resistance continues to pose a significant obstacle in the management of advanced hepatocellular carcinoma. Most hepatocellular carcinoma patients receiving Sorafenib developing resistance within 6 months. 12 Despite Lenvatinib exhibiting non-inferiority to Sorafenib in relation to overall survival, the emergence of acquired resistance remains a substantial impediment to the efficacy of Lenvatinib. In hepatocellular carcinoma, our understanding of the resistance targets and specific mechanisms of Sorafenib and Lenvatinib remains limited. Recent studies have identified a potential association between dysregulation of lipid metabolism homeostasis and the pathogenesis of hepatocellular carcinoma. The interconnection between metabolic reprogramming and the development and advancement of hepatocellular carcinoma has been acknowledged. 13–15 Dysregulated lipid metabolism plays a significant role in a variety of liver diseases, including hepatocellular carcinoma. 16 In contrast to the extensive research conducted on glucose and amino acid metabolism in hepatocellular carcinoma, there has been relatively less emphasis on investigating the influence of dysregulated lipid metabolism on the occurrence and progression of hepatocellular carcinoma. The objective of this review is to provide an overview of the dysregulated lipid metabolism in hepatocellular carcinoma, emphasizing its potential significance and impact on the resistance development to Sorafenib and Lenvatinib. Furthermore, the potential of targeting lipid metabolism as a novel strategy to overcome resistance to targeted therapy in hepatocellular carcino -Abstract Truncated-
oncology